Protocol Ledger

NCT04825860 · Phase II/III · TERMINATED

A Clinical Trial to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic People With Schizophrenia, Followed by an Open-label Extension Phase

Interventional Phase II/III clinical trial protocol NCT04825860 sponsored by Sumitomo Pharma Co in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-03-29 Enrollment: 83 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04825860
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)83 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04825860
Protocol FieldVerified Registry Value
NCT IdentifierNCT04825860
Consolidated Lead SponsorSumitomo Pharma Co
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase II/III
Overall Recruitment StatusTERMINATED
Registered Enrollment83 participants (ACTUAL)
Registered Start Date2021-03-29
WhyStopped ClassificationStrategic / Business / Sponsor Decision

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI